eCIO Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

eCIO Inc’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15	Closed	-$6.8K	–	173
2025 Q4	$6.8K	Buy	+15	New	+$6.46K	﹤0.01%	184
2025 Q2	–	Sell	-15	Closed	-$7.27K	–	175
2025 Q1	$7.27K	Buy	+15	New	+$6.99K	﹤0.01%	451

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

eCIO Inc's VRTX Position: Q1 2026 in Review

eCIO Inc sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 15 shares — an estimated $6.8K sold.

eCIO Inc first reported a position in VRTX in Q1 2025 and held it in 2 quarters. The position peaked at $7.27K in Q1 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

eCIO Inc reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
eCIO Inc sold 15 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.8K.
eCIO Inc first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 2 quarters.
eCIO Inc's Vertex Pharmaceuticals position peaked at $7.27K in Q1 2025.
1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on eCIO Inc's 13F filing for Q1 2026, filed 14 Apr 2026.